In the style of the film Jerry Maguire where Jerry sets out his manifesto for the “Future of Our Business,” we’re taking an extended look at the Future of Natural Killer (NK) cell therapy through the eyes of one of the leading global translational scientists in the NK field, Dr Todd Fehniger, who is at Washington University in St Louis.

In the second part of the ASH20 interview Dr Fehniger kindly gave BSB around key trials and concepts, we’re offering in a more focused look at engineered NK cells and, in particular, CAR-NK cells, as well as several other key areas to watch out for in this emerging niche…

To learn more from our oncology analysis and get a heads up on the latest insights and analysis pertaining to NK cell developments, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by